(2108–2153) Spondyloarthritis Including PsA – Treatment Poster III: PsA

Poster abstract session.

Presentations:

• 1:00 PM – 3:00 PM Eastern Time

  Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naïve Adults with PsA
  

  Abstract Poster Presenter: Stefan Siebert, MD, PhD – University of Glasgow
• 1:00 PM – 3:00 PM Eastern Time

  Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
  

  Abstract Poster Presenter: Arthur Kavanaugh, MD – UCSD
• 1:00 PM – 3:00 PM Eastern Time

  Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
  

  Abstract Poster Presenter: Laure Gossec, MD, PhD – Sorbonne Universite
• 1:00 PM – 3:00 PM Eastern Time

  Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
  

  Abstract Poster Presenter: Dafna Gladman, MD, FRCPC – University of Toronto, Toronto Western Hospital
• 1:00 PM – 3:00 PM Eastern Time

  Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
  

  Abstract Poster Presenter: Christopher T. Ritchlin, MD, MPH – University of Rochester Medical Center
• 1:00 PM – 3:00 PM Eastern Time

  Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies
  

  Abstract Poster Presenter: Dennis McGonagle, MD, PhD – Uni of Leeds
• 1:00 PM – 3:00 PM Eastern Time

  Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study
  

  Abstract Poster Presenter: Iain McInnes, PhD, FRCP – University of Glasgow
• 1:00 PM – 3:00 PM Eastern Time

  Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Post Hoc Analysis Through 2 Years of a Phase 3 Study
  

  Abstract Poster Presenter: Laura C. Coates, MD, PhD – University of Oxford
• 1:00 PM – 3:00 PM Eastern Time

  Assessment of the Ultrasound and Clinical Response to Apremilast Using a Joint-periarticular-nail Ultrasound Index and Clinical Evaluation in Patients with Active Psoriatic Arthritis
  

  Abstract Poster Presenter: Juan Jose De Agustin de Oro, Sr., MD, PhD – Vall D’Hebron University Hospital
• 1:00 PM – 3:00 PM Eastern Time

  Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies
  

  Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
• 1:00 PM – 3:00 PM Eastern Time

  Achieving Increasingly Stringent Clinical Disease Control Criteria Is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
  

  Abstract Poster Presenter: Jessica Walsh, MD – University of Utah and Salt Lake City Veterans Affairs
• 1:00 PM – 3:00 PM Eastern Time

  Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
  

  Abstract Poster Presenter: M. Elaine Husni, MD, MPH – Cleveland Clinic
• 1:00 PM – 3:00 PM Eastern Time

  Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of 11 Phase 2/3 Clinical Studies in Psoriasis and Psoriatic Arthritis
  

  Abstract Poster Presenter: Proton Rahman, MD – Memorial University
• 1:00 PM – 3:00 PM Eastern Time

  Long-term Persistence of Second-line Biologics in Psoriatic Arthritis Patients with Prior TNF Inhibitor Exposure: A Nationwide Cohort Study from the French Health Insurance Database
  

  Abstract Poster Presenter: Laura Pina Vegas, MD, MPH – Henri Mondor University Hospital (APHP), Rheumatology Department
• 1:00 PM – 3:00 PM Eastern Time

  Bimekizumab Treatment Improves Health-Related Quality of Life in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
  

  Abstract Poster Presenter: Dafna Gladman, MD, FRCPC – University of Toronto, Toronto Western Hospital
• 1:00 PM – 3:00 PM Eastern Time

  Hierarchical Ranking of Biologic Disease-Modifying Antirheumatic Drugs and Targeted Systemic Therapies for Psoriatic Arthritis: A Network Meta-analysis
  

  Abstract Poster Presenter: Adela Castro, MD – Hamilton Physician Group-Specialty Care
• 1:00 PM – 3:00 PM Eastern Time

  Immunological Differences Between PsA Patients Who Are Tumor Necrosis Factor Inhibitor-Naïve and Who Have Inadequate Response to Tumor Necrosis Factor Inhibitors
  

  Abstract Poster Presenter: Atul Deodhar, MD – Oregon Health & Science University
• 1:00 PM – 3:00 PM Eastern Time

  Effects of Treatment with Risankizumab on Minimal Disease Activity and Disease Activity in Psoriatic Arthritis: An Analysis of the KEEPsAKE-1 and -2 Trials
  

  Abstract Poster Presenter: Joseph F. Merola, MD, MSc – Harvard Medical School, Brigham and Women's Hospital
• 1:00 PM – 3:00 PM Eastern Time

  Impact of Risankizumab on Enthesitis and Dactylitis: Integrated Analysis of the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
  

  Abstract Poster Presenter: Saakshi Khattri, MD, MBBS – Mount Sinai Medical Center
• 1:00 PM – 3:00 PM Eastern Time

  Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years
  

  Abstract Poster Presenter: Laura C. Coates, MD, PhD – University of Oxford
• 1:00 PM – 3:00 PM Eastern Time

  Consistent Long-Term Guselkumab Efficacy Across Psoriatic Arthritis Domains Irrespective of Baseline Patient Characteristics
  

  Abstract Poster Presenter: Iain McInnes, PhD, FRCP – University of Glasgow
• 1:00 PM – 3:00 PM Eastern Time

  Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
  

  Abstract Poster Presenter: Signe Holm Nielsen, PhD – Nordic Bioscience
• 1:00 PM – 3:00 PM Eastern Time

  Apremilast in Bio-Naïve Patients with Early Psoriatic Arthritis: A National, Real-Life, Multicenter, Non-Interventional, Prospective, 52-week Cohort Study
  

  Abstract Poster Presenter: Gkikas Katsifis, MD, PhD, RhMSUS – Naval Hospital of Athens
• 1:00 PM – 3:00 PM Eastern Time

  Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis
  

  Abstract Poster Presenter: William Tillett, PhD, MBChB – Royal National Hospital for Rheumatic Diseases
• 1:00 PM – 3:00 PM Eastern Time

  Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor: As Assessed by Laboratory Parameters – Results from a Phase 2 Trial in Psoriatic Arthritis and 2 Phase 3 Trials in Psoriasis
  

  Abstract Poster Presenter: Roy Fleischmann, MD – Metroplex Clinical Research Center and University of Texas Southwestern Medical Center
• 1:00 PM – 3:00 PM Eastern Time

  Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis
  

  Abstract Poster Presenter: Oliver FITZGERALD, MD – UCD
• 1:00 PM – 3:00 PM Eastern Time

  Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program
  

  Abstract Poster Presenter: Subhashis Banerjee, MD – Bristol Myers Squibb
• 1:00 PM – 3:00 PM Eastern Time

  Evaluation of Candidate Protein Biomarkers to Predict Treatment Response in Patients with Psoriatic Arthritis
  

  Abstract Poster Presenter: Stephen R. PENNINGTON, PhD – University College Dublin
• 1:00 PM – 3:00 PM Eastern Time

  Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis: Achievement of Minimal Disease Activity and Its Components
  

  Abstract Poster Presenter: Arthur Kavanaugh, MD – UCSD
• 1:00 PM – 3:00 PM Eastern Time

  Impact of Patient Characteristics, Including Sex, on the Efficacy of Upadacitinib Compared with Adalimumab in Patients with Psoriatic Arthritis
  

  Abstract Poster Presenter: Lihi Eder, MD, PhD – University of Toronto
• 1:00 PM – 3:00 PM Eastern Time

  Real-world Persistence and Treatment Patterns in Psoriatic Arthritis Patients Treated with Anti-IL17 Therapy
  

  Abstract Poster Presenter: Sebastian Moyano, MD – Lilly
• 1:00 PM – 3:00 PM Eastern Time

  Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial
  

  Abstract Poster Presenter: Iain McInnes, PhD, FRCP – University of Glasgow
• 1:00 PM – 3:00 PM Eastern Time

  Exposure-Adjusted Incidence Rate for Adverse Events of Special Interest in Patients with Psoriatic Arthritis Treated with Apremilast
  

  Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
• 1:00 PM – 3:00 PM Eastern Time

  How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? - Exploratory Results from a Phase 3b Study
  

  Abstract Poster Presenter: Maria Antonietta D'Agostino, PhD – Università Cattolica del Sacro Cuore
• 1:00 PM – 3:00 PM Eastern Time

  Strong Correlation Between Short- vs Long-form Composite Measures of Psoriatic Arthritis Disease Activity in a TNFi-IR Population Treated with Guselkumab: Data from the Phase 3b COSMOS Trial
  

  Abstract Poster Presenter: William Tillett, PhD, MBChB – Royal National Hospital for Rheumatic Diseases
• 1:00 PM – 3:00 PM Eastern Time

  Effect of Upadacitinib and Adalimumab on Residual Pain Among Patients with Psoriatic Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
  

  Abstract Poster Presenter: Louis Bessette, MD, MSc – Centre de l'Ostéoporose et de Rhumatologie de Québec
• 1:00 PM – 3:00 PM Eastern Time

  JAK Inhibition Re-balances Gene Expression Profile of Circulating Immune Cells in Patients with Psoriatic Arthritis
  

  Abstract Poster Presenter: Maria Gabriella Raimondo, MD – Uniklinikum Erlangen, Department of Medicine 3, Rheumatology and Immunology
• 1:00 PM – 3:00 PM Eastern Time

  Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Trials
  

  Abstract Poster Presenter: Andrew Ostor, MD – Monash Uni & ANU
• 1:00 PM – 3:00 PM Eastern Time

  Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years
  

  Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
• 1:00 PM – 3:00 PM Eastern Time

  Cumulative Dose and Exposure Time to Methotrexate Were Not Shown to Be Predictors of Hepatic Fibrosis by Elastography - A Monocentric Cohort Study
  

  Abstract Poster Presenter: Filipe Pinheiro, Sr, MD – Centro Hospitalar Universitário de São João
• 1:00 PM – 3:00 PM Eastern Time

  WITHDRAWN
• 1:00 PM – 3:00 PM Eastern Time

  Cycling versus Swapping Strategies in Psoriatic Arthritis: Results from the Rheumatic Diseases Portuguese Register
  

  Abstract Poster Presenter: Maria Francisca Alves Guimarães, MD – Unidade Local de Saúde do Alto Minho
• 1:00 PM – 3:00 PM Eastern Time

  Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study
  

  Abstract Poster Presenter: Carlo Salvarani, MD – Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia
• 1:00 PM – 3:00 PM Eastern Time

  Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial
  

  Abstract Poster Presenter: Kurt de Vlam, MD, PhD – University Hospitals Leuven
• 1:00 PM – 3:00 PM Eastern Time

  Depression and Other Neurological Disorders Are Associated with Biologic DMARD Failure in Psoriatic Arthritis
  

  Abstract Poster Presenter: Nicoletta Luciano – IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology
• 1:00 PM – 3:00 PM Eastern Time

  Key Differences Between US Rheumatologists’ and Dermatologists’ Management of Psoriatic Arthritis
  

  Abstract Poster Presenter: Maxine Yarnall, BS – Spherix Global Insights